GUCY2C may protect Parkinson’s nerve cells: Mouse study
GUCY2C — a protein found mainly in the gut, but also in the brain — appears to be produced in…
Articles by Margarida Maia, PhD
Alpha-synuclein process may be therapeutic target in Parkinson’s
Clumps of alpha-synuclein, the protein responsible for nerve cell death in Parkinson’s disease, initially form under medium salt conditions.
Partnership aims to ID definitive biomarkers for Parkinson’s disease
A new collaboration dubbed the Accelerating Medicines Partnership in Parkinson’s Disease and Related Disorders, or simply AMP PDRD, will…
Tainted water at Camp Lejeune tied to faster Parkinson’s progression
U.S. Marine Corps and Navy personnel exposed to trichloroethylene (TCE) and other industrial chemicals in drinking water at Camp Lejeune…
Dopaminergic neurons play role in short-term memory: Mouse study
Dopamine-producing nerve cells, or dopaminergic neurons, in the midbrain may play a role in the temporary storage of information in…
LSVT Loud bests UK standard Parkinson’s speech therapy in trial
An intensive course in the Lee Silverman Voice Treatment, known as LSVT Loud, may be the best strategy to help…
RXR agonist, IRX4204, safely eases motor symptoms in Phase 1 trial
Once-daily treatment with IRX4204, an oral small molecule being developed by Io Therapeutics, showed a potential to safely…
Low-dose TED-A9 cell therapy eases Parkinson’s motor symptoms: Study
The first three Parkinson’s disease patients who received a low dose of TED-A9, an investigational stem cell-based therapy being…
Virtual reality game may help Parkinson’s patients in gait training
Combining gait training with virtual reality and gamification elements — when game-like features are added to non-game activities — may…
Coffee, tobacco, aspirin offset Parkinson’s disease’s genetic risk
People with a genetic predisposition to Parkinson’s disease are more likely to have early-onset symptoms, but lifestyle factors such…